The MAYO PROTEIN CORE (MPC) was integrated as a shared resource of the Mayo Clinic Cancer Center in 1992, and since that time the core has experienced a rapid growth and continued expansion of its services by Cancer Center members. The facility has supported a broad diversity of projects related to cancer research, and has thus served in an indispensable capacity to members of the Mayo Clinic Cancer Center. The user base of this resource has steadily increased from 21 center members in 1991, to 47 members in 1997. The seven full-time staff of the resource provide a broad range of services related to protein analysis, synthesis and isolation to members in both basic and clinical sciences. The current services provided to Cancer Center members are: (1) N-terminal protein sequencing; (2) C-terminal protein sequencing by an alkylated-thiohydantoin chemistry; (3) Protein digestion and peptide separation by capillary liquid chromatography (cLC); (4) Quantitative and qualitative amino and analysis; (5) Solid phase peptide synthesis by Fmoc methods; (6) Production of peptide/protein specific immunogens on KLH/BSA carriers; (7) Protein/peptide purification by reverse phase HPLC and FPLC, and (8) Computer analysis of protein sequences for synthetic peptide design. The resource will also be offering the following new services to Cancer Center members comprising; (9) Two dimensional polyacrylamide gel electrophoresis (2-D PAGE); (10) Chemical synthesis of large polypeptides and small synthetic proteins; (11) Peptide nucleic acid (PNA) synthesis, and (12) Computational chemistry and molecular modeling of proteins and polypeptides.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA015083-28
Application #
6652727
Study Section
Project Start
2002-08-28
Project End
2003-02-28
Budget Start
Budget End
Support Year
28
Fiscal Year
2002
Total Cost
$72,259
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
City
Rochester
State
MN
Country
United States
Zip Code
55905
Lu, Yingchang; Beeghly-Fadiel, Alicia; Wu, Lang et al. (2018) A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. Cancer Res 78:5419-5430
Dasari, Surendra; Newsom, Sean A; Ehrlicher, Sarah E et al. (2018) Remodeling of skeletal muscle mitochondrial proteome with high-fat diet involves greater changes to ?-oxidation than electron transfer proteins in mice. Am J Physiol Endocrinol Metab 315:E425-E434
Nowsheen, Somaira; Aziz, Khaled; Aziz, Asef et al. (2018) L3MBTL2 orchestrates ubiquitin signalling by dictating the sequential recruitment of RNF8 and RNF168 after DNA damage. Nat Cell Biol 20:455-464
Razidlo, Gina L; Burton, Kevin M; McNiven, Mark A (2018) Interleukin-6 promotes pancreatic cancer cell migration by rapidly activating the small GTPase CDC42. J Biol Chem 293:11143-11153
Wu, Dongyan; Yang, Haitao; Winham, Stacey J et al. (2018) Mediation analysis of alcohol consumption, DNA methylation, and epithelial ovarian cancer. J Hum Genet 63:339-348
Leon-Ferre, Roberto A; Polley, Mei-Yin; Liu, Heshan et al. (2018) Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer. Breast Cancer Res Treat 167:89-99
Jahanseir, Khadijeh; Xing, Deyin; Greipp, Patricia T et al. (2018) PDGFB Rearrangements in Dermatofibrosarcoma Protuberans of the Vulva: A Study of 11 Cases Including Myxoid and Fibrosarcomatous Variants. Int J Gynecol Pathol 37:537-546
Painter, Jodie N; O'Mara, Tracy A; Morris, Andrew P et al. (2018) Genetic overlap between endometriosis and endometrial cancer: evidence from cross-disease genetic correlation and GWAS meta-analyses. Cancer Med 7:1978-1987
Yu, Jia; Qin, Bo; Moyer, Ann M et al. (2018) DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine. J Clin Invest 128:2376-2388
Sugihara, Takaaki; Werneburg, Nathan W; Hernandez, Matthew C et al. (2018) YAP Tyrosine Phosphorylation and Nuclear Localization in Cholangiocarcinoma Cells Are Regulated by LCK and Independent of LATS Activity. Mol Cancer Res 16:1556-1567

Showing the most recent 10 out of 1129 publications